世界卫生组织（WHO）、国际细胞学学会和国际癌症研究机构已开发一种标准化胰胆管细胞病理报告的方法。《WHO胰胆管细胞病理报告系统》（WHO系统）修订了2015年发表的《Papanicolaou细胞病理学会胰胆管细胞学报告体系（PSC系统）》，将原先的6个PSC分类替换为以下7个分类：「不足/不充分/无诊断价值」、「良性/阴性恶性」、「非典型」、「低风险/级别胰胆管肿瘤（PaN-low）」、「高风险/级别胰腺肿瘤（PaN-High）」、「可疑恶性」和「恶性」。在PSC系统中，只有一个「肿瘤性」病变分类，包括良性肿瘤和称为「其他肿瘤性」的第二组，其中主要是肿瘤前期内导管性肿瘤，特别是内导管性乳头状黏液性肿瘤和低度恶性肿瘤（胰腺神经内分泌肿瘤和实性假乳头状瘤）。在WHO系统中，几乎没有恶性风险的良性肿瘤被归入「良性」类别，低度恶性肿瘤（胰腺神经内分泌肿瘤和实性假乳头状瘤）被归入「恶性」类别，按照WHO《消化系统肿瘤分类第5版》的规定。这个系统通过上皮的细胞形态分级将管道的非侵入性前病变分为PaN-low和PaN-high，其恶性风险明显不同。在每个类别中，概述了关键的诊断细胞病理学特征和辅助诊断和预后评估研究，以及诊断对患者护理和管理的影响。报告和诊断管理选择考虑到低收入和中等收入国家诊断和预后辅助检测模式的差异。版权所有©2023，由Elsevier公司出版。

The World Health Organization (WHO), the International Academy of Cytology, and the International Agency for Research on Cancer have developed an approach to standardized reporting of pancreaticobiliary cytopathology. The WHO Reporting System for Pancreaticobiliary Cytopathology (WHO System) revises the Papanicolaou Society of Cytopathology (PSC) System for Reporting Pancreaticobiliary Cytology published in 2015 and replaces the 6 PSC categories with 7 categories: "Insufficient/Inadequate/Nondiagnostic"; "Benign/Negative for malignancy"; "Atypical"; "Pancreaticobiliary neoplasm, low risk/grade (PaN-low)"; "Pancreatic neoplasm, high risk/grade (PaN-High)"; "Suspicious for malignancy"; and "Malignant". In the PSC system, there is a single category for "Neoplastic" lesions that includes 2 groups, 1 for benign neoplasms and 1 named "Neoplastic-other", dominated by premalignant intraductal neoplasms primarily intraductal papillary mucinous neoplasms and low-grade malignant neoplasms (pancreatic neuroendocrine tumors (PanNET) and solid pseudopapillary neoplasms (SPN). In the WHO System, benign neoplasms with virtually no risk of malignancy are included in the "Benign" category and low-grade malignancies (PanNET and SPN) are included in the "Malignant" category, as per the 5th edition of the WHO Classification of Digestive System Tumors, while the non-invasive pre-malignant lesions of the ducts are divided by the cytomorphological grade of the epithelium into PaN-low and PaN-high with distinctly different risks of malignancy. Within each category, key diagnostic cytopathologic features and the ancillary studies for diagnostic and prognostic evaluation, as well as the implications of diagnosis for patient care and management, are outlined. Reporting and diagnostic management options recognize the variations in the availability of diagnostic and prognostic ancillary testing modalities in low- and middle-income countries.Copyright © 2023. Published by Elsevier Inc.